Hepatocyte growth factor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Nitriles are isomeric with isonitriles (isocyanides). These also contain a C≡N triple bond; however, the substituent is bonded via the nitrogen atom, which results in a zwitterionic structure. Compounds in which an oxygen atom is bonded to the carbon atom of a C≡N group are referred to as cyanates. If the oxygen atom is replaced by a sulfur or selenium atom, the compounds are termed thiocyanates or selenocyanates. If the cyano group is bonded to a nitrogen atom, the compound is referred to as a cyanamide. In addition to nitriles, other classes of compounds are known that contain a C≡N triple bond in which the nitrogen atom forms a fourth bond and is therefore positively charged. In nitrile oxides, an oxygen atom is additionally bonded to the nitrogen atom. If this atom is sulfur or another nitrogen atom instead, the compounds are referred to as nitrile sulfides or nitrilimines, respectively. If the nitrogen atom of the nitrile is protonated or carries an additional organic substituent, the compound is a nitrilium ion. If the nitrogen atom carries an organic substituent bearing a negatively charged carbon atom, the species is a nitrile ylide, a subclass of ylides.
Cyclic amines—Cyclic amines are either secondary or tertiary amines. Examples of cyclic amines include the 3-membered ring aziridine and the six-membered ring piperidine. N-methylpiperidine and N-phenylpiperidine are examples of cyclic tertiary amines.
These models have a prominent bonnet scoop. At about the same time a all-wheel-drive model was introduced in Japan, either with a 1.6-litre petrol or the Isuzu turbo-diesel. The 4WD cars can be easily identified by having been equipped with the federalized front (but not rear) bumper, including side marker lights. The rare North American ES model came with the Miata (NA)'s 1.8-litre twin-cam engine (though the internals were not entirely the same), all-wheel disc brakes, and dual stabilizer bars. The same car went on sale in Australia in the second half of 1994 with a fully featured BP-ZE engine. The Protegé became classified as a "compact car" for the 1995 model year in North America. A version with Mazdaspeed accessories was released in Japan and Philippines. It came equipped with Mazdaspeed wrap around bodykit, Mazdaspeed rear spoiler, Momo steering wheel, 15-inch Rota Astral wheels wrapped in 195/55R15 Bridgestone Potenza RE01 tires, Mazdaspeed strut tower bar, Eibach springs, gas-charged shock absorbers, swaybars and Mazdaspeed exhaust made by Yumex. The Familia/Protegé/323 was facelifted in October 1996, with a newer somewhat calmer style. This generation was discontinued in 1998 in most markets, but continued to be available in some markets until 1999 or 2000. For example, the 3-door hatchback was available in Europe until October 2000.
Sources: en.wikipedia.org
== In film == Penicillin: The Magic Bullet is a 2006 Australian film production written by Gordon Glenn and financed by the Film Finance Corporation and Arcimedia Productions in association with Film Victoria. Breaking The Mould is a 2009 historical drama that tells the story of the development of penicillin in the 1930s and 1940s, by the group of scientists at Oxford headed by Florey at the William Dunn School of Pathology. The film stars Dominic West as Florey, Denis Lawson as Fleming, and Oliver Dimsdale as Chain; and was written by Kate Brooke and directed by Peter Hoar.
In addition to regulating the experiments that were conducted, the guidelines also forbade the performance of other experiments. One such experiment was the cloning of recombinant DNAs derived from highly pathogenic organisms. In addition, neither the cloning of DNA containing toxin genes nor large-scale experiments using recombinant DNAs that were able to make products that were potentially harmful to humans, animals, or plants were allowed under the guidelines. These experiments were banned because the potential biohazards could not be contained by the then-current safety precautions.
== Career == Akagha attended Southern Methodist University in Dallas, Texas, where she majored in theatre. In the early 2010s, she acted in theatrical productions in California. In 2010, she played Tiger Lily in the Pacific Conservatory of the Performing Arts's production of Peter Pan. In 2011, she acted alongside Brendan Cataldo in Leo Cortez's play, Acting Out, at the Alisal Center for the Fine Arts. In 2012, Akagha began playing the leads in various short films and making guest appearances in television series. She appeared in one-off episodes in the series Men at Work, Nashville and 2 Broke Girls. Akagha started voice acting in video games around 2016, first voicing the character "Plastic" in the game Mirror's Edge: Catalyst. In 2017, she was a voice actor for Wolfenstein II: The New Colossus, in which she provided voices for characters Barbara Casey, Zena Woodard, and Angela Cummings. In 2018, she began appearing in Marvel's Runaways television series as Tamar, a recurring, supporting role. She provided the voice for the superheroine Bumblebee in the animated series Teen Titans Go!. Bumblebee initially appeared in the show's fifth season in the episode "Forest Pirates", which aired in 2019. Akagha voiced the main character, Alyx Vance, in the virtual reality game Half-Life: Alyx. The character was first introduced in the game Half-Life 2 in 2004, being originally played by Merle Dandridge. A new actor was chosen for Alyx Vance partially due to the character's younger age and the "time gap" between this and the previous game.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.